Daclizumab

达克珠单抗

Report date: 2022/01/14 13:23:58
First In Class

Base Information

Drug NameDaclizumab
Drug Alias NameHumanised anti-Tac antibody达克珠单抗SMART anti-Tac antibody达利珠单抗达克利珠单抗 +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsRejection of organ transplantationRadiation InjuriesDiabetes Mellitus, Type 1 +[31] 
Global Approved IndicationsRejection of organ transplantationMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1997/12/10
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAbbvie IncBiogen IncF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche AgBiogen Inc
Inactive CompaniesNational Institutes Of Health Clinical Center (Cc)Radboud University Medical CenterRoche Pharma Ag +[14] 
Active IndicationsRejection of organ transplantationMultiple Sclerosis
Inactive IndicationsRadiation InjuriesDiabetes Mellitus, Type 1Psoriasis +[29] 

Other Information

ATC CodeL04AC01
Related LinksWikipediaDrugBankKEGG